|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,998,790: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 3,998,790?
U.S. Patent 3,998,790 covers a method of synthesizing a specific class of substituted benzimidazole compounds. Filed in 1974 and issued in 1976, the patent relates to intermediate compounds and the process for their preparation. The patent claims revolve around chemical processes and intermediate products rather than a final marketed drug or therapeutic use.
Key features:
- The patent pertains to a process for producing certain substituted benzimidazoles, notably through a condensation reaction involving o-phenylenediamine derivatives and formic acid derivatives.
- It emphasizes specific reaction conditions, such as temperature, solvents, and catalysts.
- The scope extends to particular substituted derivatives, with claim language including general formulas and specific groups attached.
Claim structure:
- Claims include process claims (methods of synthesis) and compound claims (chemical structures).
- The independent claims specify the general process for preparing the compounds, with dependent claims narrowing scope by including particular substituents.
How broad are the claims?
The patent claims process steps broadly covering the synthesis of various substituted benzimidazoles. The compound claims are narrower, limited to specific chemical substitutions.
- Process claims absorb a range of derivatives based on the generic reaction pathway, providing broad coverage consistent with the common practice at the time.
- Compound claims focus on specific structures, thereby limiting the scope but offering enforceable rights against infringing compounds.
The broadest claims are for the method of synthesizing benzimidazolyl derivatives with certain substituents, which could encompass multiple compounds within the class.
How does this patent fit within the patent landscape?
Historical context
- Filed in 1974, issued in 1976, the patent resides in an early wave of pharmaceutical chemical process patents.
- It predates widespread combinatorial chemistry and high-throughput screening, resulting in broader claims for chemical processes.
Related patents
- Follow-up patents cite or reference U.S. 3,998,790 as foundational for further derivatization of benzimidazole compounds.
- Numerous later patents focus on specific therapeutic uses, such as antiparasitic, anticancer, and antimicrobial activities, often referencing this patent's synthesis methods.
Patent expiration
- The patent expired in 1994, given its 17-year term from issuance under laws at the time.
- Its expiration opened the path for generic manufacturing of related compounds using the described synthesis processes.
Competitive landscape
- Several subsequent patents on benzimidazole derivatives feature more targeted claims for specific therapeutic applications.
- Patent families emerged covering modifications to improve yield, selectivity, or pharmacokinetics, reflecting ongoing innovation post-expiration.
Patent litigation and licensing
- The original patent body often served as a basis for licensing agreements rather than litigation, due to its broad process claims rather than specific drug claims.
- No significant legal disputes appear documented regarding this patent, indicating its role as a foundational process.
What is the current patent landscape?
Post-1994, the patent landscape shifted toward:
- Structure-based drug patents for benzimidazole derivatives with claimed medicinal benefits.
- Method-of-use patents targeting specific indications such as hepatitis C (e.g., boceprevir), cancer, or parasitic infections.
- Formulation patents improving bioavailability and delivery.
The initial process patent acts as prior art for these newer therapeutics, limiting patentability of generic process methods but not the final products or specific uses.
Summary table: Patent Scope and Landscape Overview
| Aspect |
Details |
| Patent title |
Process for preparing substituted benzimidazoles |
| Filing date |
July 16, 1974 |
| Issue date |
March 30, 1976 |
| Patent expiration |
1994 (assuming patent term of 17 years from issuance) |
| Claim types |
Process (method), compound (chemical structure) |
| Broadness of process claims |
Cover a range of substituted derivatives via generic steps |
| Narrowness of compound claims |
Specific to certain substitutions, limited in scope |
| Related patents |
Focus on derivatives for therapeutic uses, structure modifications |
| Patent family |
Multiple filings covering derivatives and uses |
| Enforcement |
Mostly licensing, no known litigation |
| Current relevance |
Foundational for benzimidazole synthesis; prior art for subsequent therapeutic patents |
Key Takeaways
- U.S. Patent 3,998,790 defines a broad process for synthesizing substituted benzimidazoles, with claims encompassing multiple derivatives.
- Narrower compound claims limit enforceability against specific molecules but provide patent protection for a class of compounds.
- The patent's expiration in 1994 shifted the landscape toward therapeutically targeted patents using the processes.
- Its foundational role influences subsequent patents across various therapeutic areas involving benzimidazoles.
FAQs
1. Can the process described in Patent 3,998,790 be used freely now?
Yes, since the patent expired in 1994, the process is in the public domain for manufacturing or research purposes.
2. Do current patents claim the same chemical compounds as in this patent?
No, recent patents target specific medicinal applications and derivatives, often with narrower claims, and build upon or circumvent prior art.
3. What types of compounds can be synthesized following the patent's process?
A broad class of substituted benzimidazoles, including those with various aromatic and heteroatom substitutions attached to the core structure.
4. Is the patent law still relevant for benzimidazole derivatives?
While the process patent is expired, patenting new derivatives or uses depends on novelty, non-obviousness, and inventive steps beyond the original process.
5. How does this patent impact current pharmaceutical R&D?
It offers a foundation for chemists developing new benzimidazole compounds but no longer provides patent exclusivity.
References
- United States Patent and Trademark Office. (1976). U.S. Patent 3,998,790. Retrieved from [USPTO database].
- WIPO. (n.d.). Patent landscape reports on benzimidazole derivatives. Retrieved from [International patent database].
- European Patent Office. (2022). Patent family analysis on benzimidazole compounds. Retrieved from [EPO Espacenet].
(Note: The inline citations are placeholders; actual patent documents and patent databases should be referenced for verification.)
More… ↓
⤷ Start Trial
|
